NEW YORK (GenomeWeb) – After releasing a draft document last month updating its recommendations regarding the use of molecular tests to guide chemotherapy decisions for breast cancer patients, the UK's National Institute for Health and Care Excellence (NICE) is now evaluating comments from stakeholders ahead of an expected finalization in May.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.